Mode
Text Size
Log in / Sign up
Phase 3 N=498 Randomized Prevention

Simplifying the Rabies Pre-exposure Vaccination

Rabies

Enrolled (actual)
498
Serious AEs
0.6%
Results posted
Mar 2019
Primary outcome: Primary: Number of Participants With a Boostability of the Rabies Antibodies After Booster Vaccination — 185; 183 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Human Diploid Cell Vaccine (HDCV) rabies vaccine (Biological)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Institute of Tropical Medicine, Belgium
Primary completion
Jan 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With a Boostability of the Rabies Antibodies After Booster Vaccination
185; 183
SECONDARY
Number of Participants With a Rabies Serology More Than 0.5IU/ml After Primary Vaccination
231; 238
SECONDARY
Number of Particpants With a Rabies Serology More Than 10IU/ml After Primary and Booster Vaccination
189; 167
SECONDARY
Number of Particpants Experiencing Adverse Events
190; 190
SECONDARY
Number of Participants Experiencing Serious Adverse Events
1; 2

Summary

Rabies is a viral zoonosis that causes an encephalitis, almost invariably fatal. It is widely distributed across the globe: the World Health Organization (WHO) estimates that about 2,4 billion people live in endemic areas for canine rabies. Vaccination of domestic animals is limited to industrialized and middle-income countries. The development of clinical rabies can be prevented through timely immunization after exposure: however, preventive vaccination simplifies the post-exposure procedure considerably, as immunoglobulins are no longer needed and less vaccine administrations are scheduled. Pre-exposure prophylaxis consists of an intramuscular (IM)of intradermal (ID) dose given on days 0, 7 and 21 or 28. The development of immunological memory after this vaccination is critical for the establishment of long lasting immunity. Subjects receiving a booster dose 1 year after pre-exposure prophylaxis segregate themselves into 'good' and 'poor' responders; the former may not need further boosters for 10 years, whereas the latter may need more frequent boosters. Until recently, guidelines in travel medicine recommended pre-exposure vaccination only for some risk groups. Since recent studies have shown the effectiveness of the ID vaccination, the policies are changing towards pre-exposure vaccination for a larger population, including travelers to endemic regions, where immunoglobulins and vaccine are often not readily available. Based on the above, the investigators must stress the concept of "boostability" after a risk exposure. However, the current pre-exposure vaccination scheme could be improved: a schedule of 1 week would be less time consuming, would improve compliance and give less interference with other prophylaxis measures, e.g. mefloquine. Two small studies suggest that a schedule of 1 week interval is as effective and immunogenic as the standard one. The investigators will investigate whether the accelerated schedule is as effective as the classical schedule, by carrying out a randomized, non-inferiority study.

Eligibility Criteria

Inclusion Criteria

  • Willingness to provide written consent
  • Seronegative for rabies
  • Belgian soldiers who are deployable and visit the Travel clinic in Brussels during their preparation phase before deployment OR military students at the schools of Belgian Defense are eligible in preparation of an overseas exercise or during the scheduled vaccination program at the end of their studies
  • Prepared to follow the study schedule

Exclusion Criteria

  • Subjects who have had rabies vaccination (complete or incomplete) in the past due to post-exposure prophylaxis.
  • Subjects with a known allergy to one of the components of the vaccine.
  • Immune depressed persons or intake of immunodepressant medication.
  • Subjects who take mefloquine
  • Planned deployment to overseas areas within 35 days.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01388985). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search